MOUNTAIN VIEW, CA -- (Marketwired) -- 11/03/15 -- VIVUS, Inc.(NASDAQ: VVUS) (the "Company"), a biopharmaceutical company commercializing Qsymia^® (phentermine and topiramate extended-release) capsules CIV for the treatment of obesity, today announced the following presentations at Obesity Week 2015, Los Angeles Convention Center. Posters will be available for viewing throughout the program (Wednesday, November 4, 2015 through Friday, November 6, 2015), with author(s) available for Q&A during the session as noted.

Abstract Title: Effects of Phentermine and Topiramate Extended-Release (PHEN/TPM ER) on Weight Loss (WL) in Patients With a Baseline Body Mass Index (BMI) ≥45 kg/m ²
Authors: Scott Kahan, MD, MPH; W. Timothy Garvey, MD; Roman Dvorak, MD, PhD
Date/Time: Poster Session 1, Wednesday, November 4, 2015, 11:45am -- 1:30pm PT
Location: Los Angeles Convention Center, Exhibit Hall

Abstract Title: Budget Impact of Phentermine and Topiramate Extended-Release (PHEN/TPM ER) in Patients who are Overweight or Obese With Prediabetes or Type 2 Diabetes Mellitus (T2DM)
Authors: Sunil Karnawat, PhD; Sarah A. Odeh, BS
Date/Time: Poster Session 1, Wednesday, November 4, 2015, 11:45am -- 1:30pm PT
Location: Los Angeles Convention Center, Exhibit Hall

Abstract Title: Budget Impact Over 2 Years of Treatment With Phentermine and Topiramate Extended-Release (PHEN/TPM ER) in an Overweight/Obese Population
Authors: Sunil Karnawat, PhD; Sarah A. Odeh, BS
Date/Time: Poster Session 1, Wednesday, November 4, 2015, 11:45am -- 1:30pm PT
Location: Los Angeles Convention Center, Exhibit Hall

About Qsymia

Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obese) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.

Important Safety Information

Qsymia^® (phentermine and topiramate extended-release) capsules CIV is contraindicated in pregnancy; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); or in patients with hypersensitivity to sympathomimetic amines, topiramate, or any of the inactive ingredients in Qsymia.

Qsymia can cause fetal harm. Females of reproductive potential should have a negative pregnancy test before treatment and monthly thereafter and use effective contraception consistently during Qsymia therapy. If a patient becomes pregnant while taking Qsymia, treatment should be discontinued immediately, and the patient should be informed of the potential hazard to the fetus.

The most commonly observed side effects in controlled clinical studies, 5% or greater and at least 1.5 times placebo, include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.

About VIVUS

VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ended December 31, 2014 as filed on February 25, 2015 and as amended by the Form 10-K/A filed on April 30, 2015, and periodic reports filed with the Securities and Exchange Commission.

VIVUS, Inc.
Dana B. Shinbaum
Corporate Development & Investor Relations
shinbaum@vivus.com
650-934-5200

Investor Relations:
The Trout Group
Brian Korb
Managing Director
bkorb@troutgroup.com
646-378-2923

Source: VIVUS, Inc.

News Provided by Acquire Media